BioCentury | Feb 7, 2019
Clinical News

Aminex shows MYCN is a regulator of the polyamine pathway

...target MYCN. The company is developing a combination therapy comprising small molecule polyamine uptake inhibitor AMXT 1501...
...and transport in patient-derived neuroblastoma cells and mouse models of neuroblastoma. In neuroblastoma cell lines, AMXT 1501...
...combination decreased tumor growth and increased survival compared with either therapy alone. Aminex is testing AMXT 1501...
BioCentury | Feb 1, 2019
Preclinical News

Aminex shows MYCN is a regulator of the polyamine pathway

...target MYCN. The company is developing a combination therapy comprising small molecule polyamine uptake inhibitor AMXT 1501...
...and transport in patient-derived neuroblastoma cells and mouse models of neuroblastoma. In neuroblastoma cell lines, AMXT 1501...
...combination decreased tumor growth and increased survival compared with either therapy alone. Aminex is testing AMXT 1501...
BioCentury | Jun 22, 2018
Financial News

Aminex raises $10M, starts Phase I cancer trial

...The company also said it dosed the first patient in a Phase I trial of AMXT 1501...
...Aminex spokesperson told BioCentury data are due in 2H19. The 52-patient study is to evaluate AMXT 1501...
...2019. The company has raised about $19 million to date. Aminex Therapeutics Inc., Seattle, Wash. Sandi Wong AMXT 1501 Aminex...
BioCentury | Jun 20, 2018
Financial News

Aminex raises $10M, starts Phase I cancer trial

...company said Wednesday that it dosed the first patient in a Phase I trial of AMXT 1501...
...Aminex spokesperson told BioCentury data are due in 2H19. The 52-patient study is to evaluate AMXT 1501...
Items per page:
1 - 4 of 4